The MarketReader Minute
💊 BioNTech Declines on Revenue Miss; Protagonist Therapeutics Soars with Positive Study Results | Biotech Sector Insights
Among the ETF's holdings, BioNTech SE reported a net profit for Q4 2024 that was lower than the previous year, alongside total revenue that fell short of prior estimates